Article: Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma
| Title | Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Authors | Law, EWL1 Cheung, AKL1 Kashuba, VI6 Pavlova, TV6 Zabarovsky, ER3 6 Lung, HL1 Cheng, Y1 Chua, D1 5 LaiWan Kwong, D1 Tsao, SW1 Sasaki, T4 Stanbridge, EJ2 Lung, ML1 | ||||||||||||
| Keywords | anti-angiogenic fibulin-2 methylation nasopharyngeal carcinoma tumor suppressor VEGF | ||||||||||||
| Issue Date | 2012 | ||||||||||||
| Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | ||||||||||||
| Citation | Oncogene, 2012, v. 31 n. 6, p. 728-738 [How to Cite?] DOI: http://dx.doi.org/10.1038/onc.2011.272 | ||||||||||||
| Abstract | Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved. | ||||||||||||
| ISSN | 0950-9232 2011 Impact Factor: 6.373 2011 SCImago Journal Rankings: 1.216 | ||||||||||||
| DOI | http://dx.doi.org/10.1038/onc.2011.272 | ||||||||||||
| ISI Accession Number ID | WOS:000300222100006
Funding Information: This work was supported by University Grants Council Area of Excellence grant AoE/M-06/08 to MLL and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute, and Karolinska Institute to ERZ. | ||||||||||||
| References | References in Scopus | ||||||||||||
| Grants | Centre for Nasopharyngeal Carcinoma Research |
| dc.contributor.author | Law, EWL | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| dc.contributor.author | Cheung, AKL | ||||||||||||
| dc.contributor.author | Kashuba, VI | ||||||||||||
| dc.contributor.author | Pavlova, TV | ||||||||||||
| dc.contributor.author | Zabarovsky, ER | ||||||||||||
| dc.contributor.author | Lung, HL | ||||||||||||
| dc.contributor.author | Cheng, Y | ||||||||||||
| dc.contributor.author | Chua, D | ||||||||||||
| dc.contributor.author | LaiWan Kwong, D | ||||||||||||
| dc.contributor.author | Tsao, SW | ||||||||||||
| dc.contributor.author | Sasaki, T | ||||||||||||
| dc.contributor.author | Stanbridge, EJ | ||||||||||||
| dc.contributor.author | Lung, ML | ||||||||||||
| dc.date.accessioned | 2011-06-17T09:19:16Z | ||||||||||||
| dc.date.available | 2011-06-17T09:19:16Z | ||||||||||||
| dc.date.issued | 2012 | ||||||||||||
| dc.description.abstract | Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved. | ||||||||||||
| dc.description.grant | Centre for Nasopharyngeal Carcinoma Research | ||||||||||||
| dc.description.grantcode | 101179 | ||||||||||||
| dc.description.nature | Link_to_subscribed_fulltext | ||||||||||||
| dc.identifier.citation | Oncogene, 2012, v. 31 n. 6, p. 728-738 [How to Cite?] DOI: http://dx.doi.org/10.1038/onc.2011.272 | ||||||||||||
| dc.identifier.citeulike | 9543910 | ||||||||||||
| dc.identifier.doi | http://dx.doi.org/10.1038/onc.2011.272 | ||||||||||||
| dc.identifier.epage | 738 | ||||||||||||
| dc.identifier.hkuros | 185871 | ||||||||||||
| dc.identifier.isi | WOS:000300222100006
Funding Information: This work was supported by University Grants Council Area of Excellence grant AoE/M-06/08 to MLL and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute, and Karolinska Institute to ERZ. | ||||||||||||
| dc.identifier.issn | 0950-9232 2011 Impact Factor: 6.373 2011 SCImago Journal Rankings: 1.216 | ||||||||||||
| dc.identifier.issue | 6 | ||||||||||||
| dc.identifier.openurl | ![]() | ||||||||||||
| dc.identifier.pmid | 21743496 | ||||||||||||
| dc.identifier.scopus | eid_2-s2.0-84856949774 | ||||||||||||
| dc.identifier.spage | 728 | ||||||||||||
| dc.identifier.uri | http://hdl.handle.net/10722/134395 | ||||||||||||
| dc.identifier.volume | 31 | ||||||||||||
| dc.language | eng | ||||||||||||
| dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | ||||||||||||
| dc.publisher.place | United Kingdom | ||||||||||||
| dc.relation.ispartof | Oncogene | ||||||||||||
| dc.relation.references | References in Scopus | ||||||||||||
| dc.subject | anti-angiogenic | ||||||||||||
| dc.subject | fibulin-2 | ||||||||||||
| dc.subject | methylation | ||||||||||||
| dc.subject | nasopharyngeal carcinoma | ||||||||||||
| dc.subject | tumor suppressor | ||||||||||||
| dc.subject | VEGF | ||||||||||||
| dc.title | Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma | ||||||||||||
| dc.type | Article |
Author Affiliations
- The University of Hong Kong
- UC Irvine
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- null
- Hong Kong Sanatorium and Hospital
- Södersjukhuset


